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phase of sepsis may counteract the cytokine storm. Furthermore,
stabilization of Pellino3 by inhibition of autophagy in the hypoinflammatory
phase of sepsis may improve immunity. In consideration of these two
conflictive sepsis phases, modulation of Pellino3 may provide a new strategy
for the development of a therapy approach in sepsis.
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Background: The multicomponent phagocytic NADPH oxidase produces
reactive oxygen species (ROS) after activation by microorganisms or
inflammatory mediators [1]. In the hypoinflammatory phase of sepsis,
macrophages are alternatively activated by contact with apoptotic cells or
their secretion products. This inhibits NADPH oxidase and leads to
attenuated ROS production [2] and furthermore contributes among others
to a hyporeactive host defense. Due to this immune paralysis, sepsis
patients suffer from recurrent and secondary infections [3]. We focused on
the catalytic subunit of NADPH oxidase, the transmembrane protein NOX2
[4]. We assume that after induction of sepsis the expression of NOX2 is
reduced and hence ROS production is decreased.
Methods: We induced polymicrobial sepsis in mice by cecal ligation and
puncture. The ability of peritoneal macrophages (PMs) to produce ROS was
determined by FACS via hydroethidine assay. NOX2 expression of PMs was
determined by western blot and qPCR. To elucidate the mechanism
causing mRNA destabilization, we performed in vitro experiments using
J774 macrophages. To obtain an alternatively activated phenotype,
macrophages were stimulated with conditioned medium from apoptotic
T cells (CM). By luciferase assays we figured out a 3’UTR-dependent
regulation of NOX2 mRNA stability. Assuming that a protein is involved in
the mRNA degradation, we performed a RNA pulldown with biotinylated
NOX2-3’UTR constructs followed by mass spectrometry. We verified the
role of SYNCRIP by siRNA approach. Additionally, we overexpressed NOX2
in J774 cells and analyzed the ROS production (w/wo CM treatment) by
FACS.
Results: We found an impaired expression of NOX2 at RNA and protein
level along with decreased ROS production after induction of sepsis in mice
as well as stimulating J774 macrophages with CM of apoptotic T cells. This is
due to a time-dependent NOX2 mRNA degradation depending on SYNCRIP,
a RNA-binding protein, which stabilizes NOX2 mRNA through binding to its
3’UTR under normal conditions. In line, knockdown of SYNCRIP also
decreases NOX2 mRNA expression. We assume that a CM-dependent
modification or degradation of SYNCRIP prevents its stabilizing function. As
the overexpression of NOX2 restores ROS production of CM-treated J774
cells, we assume that NOX2 expression is crucial for maintaining NADPH
activity during the hypoinflammatory phase of sepsis.
Conclusion: Our data imply a regulatory impact of SYNCRIP on NOX2
stability during the late phase of sepsis. Therefore, further understanding
of the regulation of NADPH oxidase could lead to the design of a therapy
to reconstitute NADPH oxidase function, finally improving immune
function in sepsis patients.
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Background: The ligand-activated transcription factor, peroxisome-
proliferator-activated receptor gamma (PPARg), has been shown to play an
essential role in immunosuppression during sepsis. PPARg is upregulated in
T cells of septic patients, sensitizing these cells to PPARg-dependent
apoptosis and thus contributing to T-cell depletion [1,2]. In the polymicrobial
cecum ligation and puncture (CLP) sepsis model in mice, both T-cell-specific
gene knockout (Lck-Cre PPARg
fl/fl) and systemic pharmacological PPARg
antagonism by GW9662 improved survival [3]. Because GW9662 was only
effective when applied 3 hours after CLP, we were interested to extend this
time frame. For this reason we characterized the kinetics of SPPARgMs when
administered before or in combination with the agonist thiazolidinedione,
rosiglitazone.
Methods: AP P A R g-dependent transactivation assay was used in HEK293T
cells. It is based on the vector pFA-PPARg-LBD-GAL4-DBD encoding the
hybrid protein PPARg-LBD-GAL4-DBD and the reporter vector pFR-Luc,
carrying a GAL4-responsive element in front of the Firefly luciferase gene.
These two vectors were co-transfected, in combination with a control
vector encoding Renilla luciferase (pRL-CMV) to normalize Firefly luciferase
activity for transfection efficiency. Following transfection, cells were
incubated with the SPPARgMs F-MOC and MCC-555 and the PPARg
antagonist GW9662 for different times (2 to 48 hours) and at increasing
doses (0.01 to 10 μM), with or without rosiglitazone (0.01 to 10 μM).
Transactivation was analyzed using a 96-well plate format.
Results: Rosiglitazone transactivated PPARg in a time-dependent and dose-
dependent manner, the response gradually increasing to a maximum at
48 hours with 10 μM. Low concentrations (0.01 to 0.1 μM) of SPPARgMs
F-MOC and MCC-555 and the PPARg antagonist GW9662 all exerted dose-
independent antagonistic effects at an early incubation time point (2 hours).
From 10 hours onwards, MCC-555 and GW9662, given alone, both exerted
PPARg agonistic effects, MCC-555 in parallel to responses to rosiglitazone,
but GW9662 with characteristics of partial antagonism. F-MOC showed no
dose-dependent effect at any concentration at later time points. Only
GW9662 (1 to 10 μM) was able to inhibit rosiglitazone (0.1 to 1 μM)-induced
PPARg transactivation after 10 hours.
Conclusion: Our kinetic analysis reveals clear differences in the
modulatory characteristics of PPARg inhibitors, with previously unreported
early inhibitory effects and late agonistic or partial agonistic activity. New
SPPARgMs with extended inhibitory activity may prove useful in the
therapy of sepsis.
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Background: Fatal human critical cases associated with influenza A
subtype H5N1 have been documented in Bandung, Indonesia. Of four
children, three died. We determined the level of cytokines and chemokines
in those patients.
Methods: The Luminex method was used to look for the profile of
cytokine and chemokine gene expression induced by H5N1 influenza virus
from patient’s serum.
Results: We found that H5N1 influenza virus in the dead children was a
more potent inducer of IL-6, the level being higher (17.00, 74.31, 85.75)
than in the one child who survived (4.78). The IFNg level of the fatal
causes was also higher (21.43, 31.75, 384.38) than in the one child who
recovered (5.51). This suggested that a cytokine storm may play a role in
the pathogenesis of fatal H5N1 cases.
Conclusion: The H5N1 influenza A virus is a potent inducer of
proinflammatory cytokines and chemokines. This hyperinduction of
cytokines may be relevant to mortality of children with H5N1 infection.
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Background: Sepsis-induced organ damage is a leading cause of death in
critically ill patients. Thrombopoietin (TPO) is a humoral growth factor
mainly involved in regulation of platelet number and function. High
circulating levels of TPO are detectable in septic adults and children and
are related to sepsis severity. We have previously shown a correlation
between TPO levels and platelet activation in septic burned patients,
where circulating activated platelets may cause microthrombotic events
that lead to organ damage. Our aim was to evaluate the contribution of
TPO in organ injury in a murine model of polymicrobial sepsis. To this end,
we synthesized and used a chimeric fusion protein, named mouse TPO
Receptor-Maltose Binding Protein (mTPOR-MBP), able to inhibit TPO
biological activity.
Methods: Male C57BL/6 mice were randomized to cecal ligation and
puncture-induced sepsis (CLP) or to laparotomy (sham) surgery. CLP mice
received 40 μg mTPO-MBP or sterile saline 10 minutes after surgery.
Immediately after and 6 hours after surgery all animals received 0.08 mg/kg
buprenorfin in 1.5 ml sterile saline subcutaneously. After 18 hours blood was
collected from the cava vein and used for cell count, flow cytometric
analysis of leukocyte-platelet interaction and to obtain plasma. Plasma TPO
levels were determined by ELISA. The lung and liver were excised and fixed
in 4% paraformaldehyde solution. An expert pathologist blinded to
experimental groups quantified organ damage.
Results: Plasma TPO levels were significantly higher in septic mice (nine
mice in each group). Leukocyte and platelet counts did not significantly
differ in the CLP group treated with mTPOR-MBP compared with the CLP
control group. In contrast, the percentage of monocyte-platelet
aggregates, a marker of platelet activation, was significantly reduced after
treatment with mTPOR-MBP. Moreover, TPO blockade by mTPOR-MBP
administration induced a significant reduction of histological alterations
in the lung, as evaluated by neutrophil infiltration and thickening of the
alveolar-capillary membrane, and liver tissue samples, as evaluated by the
number of microabscesses.
Conclusion: Increased circulating levels of TPO during experimental
sepsis may have a role in the development of organ damage. Inhibition
of TPO biological activity may represent a novel promising therapeutic
approach to prevent organ failure in severe sepsis.
P56
Cholecystokinin protects rats against Staphylococcus aureus-induced
sepsis
RS Saia
*, FMC Zuelli, EC Cárnio
University of Sao Paulo, Ribeirão Preto, São Paulo, Brazil
Critical Care 2012, 16(Suppl 3):P56
Background: Cholecystokinin (CCK) was firstly described as a
gastrointestinal hormone, but immune cells express their receptors,
suggesting a possible involvement of this peptide in pathophysiological
processes. Our aims were to evaluate the role of CCK on resistance against
Gram-positive Staphylococcus aureus-induced sepsis, as well as cell influx to
infectious focus. Furthermore, since nitric oxide, TNFa and IL-10 play a key
role in the innate immune system controlling bacterial infection, we also
evaluated the synthesis of these inflammatory mediators during this sepsis
model.
Methods: Male Wistar rats (180 to 200 g) received an intraperitoneal
injection of proglumide (P) (nonselective CCK receptor antagonist; 30 or
50 mg/kg) 30 minutes before bacterial S. aureus inoculum (0.5 to 1 × 10
10
CFU/animal). At 4 and 24 hours after sepsis induction, blood and
peritoneal lavage fluid (PLF) were collected for microbiological analysis,
cytokines and nitrate quantifications and also differential cell counting.
Nitrate was detected by chemiluminescence, while TNFa and IL-10 were
determined by ELISA sandwich kits.
Results: The pretreatment with P at higher dose (50 mg/kg) increased
bacteremia in comparison with the saline-injected group (2,052 ± 810.7
vs. 154.3 ± 47.0 CFU/ml, P < 0.01) at 4 hours after sepsis induction. At the
same time point, the bacterial counting in PLF increased in a dose-
dependent manner in the P-treated rats (P < 0.05). On the other hand,
only the higher P dose elevated significantly the CFU/ml in the PLF at
24 hours (97.75 ± 12.77 × 10
4 vs. 35 ± 10.05 × 10
4 CFU/ml, P < 0.05). The
plasma TNFa and nitrate concentrations were not changed by treatment
or time after sepsis induction. However, the administration of CCK
receptors antagonist reduced the TNFa production in comparison with
the control group in PLF, at both time points. The plasma IL-10
concentration increased at 4 hours in P-treated rats, while at 24 hours it
was reduced (85.83 ± 48.0 vs. 1,698 ± 265.6 pg/ml, P < 0.001). In PLF, the
rats pretreated with P reduced the IL-10 measurements (P < 0.05) when
compared with the control group. In agreement, the macrophage influx
to peritoneal infectious focus was compromised by treatment with a high
P dose at 24 hours after S. aureus-induced sepsis (3,947.73 ± 269.99 vs.
5,629.61 ± 786.90 cells/μl; P < 0.05). Moreover, the neutrophil count did
not change among the experimental groups (6,860.59 ± 211.90 vs.
6,273.54 ± 798.91 cells/μl).
Conclusion: These data suggest a protective role for CCK peptide during
S. aureus-induced sepsis, modulating the systemic and local inflammatory
response, as well as increasing the macrophage influx to the infectious
focus.
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Background: Since 1994, Polymyxin B-direct hemoperfusion (PMX-DHP)
(Toraymyxin®; Toray Medical Co., Tokyo, Japan) has been approved as
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